CN110358835A - Application of the biomarker in gastric cancer is detected, diagnosed - Google Patents
Application of the biomarker in gastric cancer is detected, diagnosed Download PDFInfo
- Publication number
- CN110358835A CN110358835A CN201910684287.7A CN201910684287A CN110358835A CN 110358835 A CN110358835 A CN 110358835A CN 201910684287 A CN201910684287 A CN 201910684287A CN 110358835 A CN110358835 A CN 110358835A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- reagent
- expression
- primer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of the biomarker in gastric cancer detection, diagnosis, the biomarker is lncRNA.Present invention firstly discovers that AC074117.10 and AC073283.7 expresses up-regulation in gastric cancer, by carrying out AUC analysis to AC074117.10 and AC073283.7, it was found that AC074117.10 and AC073283.7 diagnostic value with higher, prompt may determine that the risk whether subject suffers from gastric cancer and get a cancer of the stomach, the present invention provide gene target simultaneously for the treatment of gastric cancer by the expression of detection AC074117.10 and AC073283.7.
Description
Technical field
The invention belongs to biomedicine fields, are related to application of the biomarker in gastric cancer detection, diagnosis.
Background technique
Gastric cancer (Gastric Cancer GC) is one of most common malignant tumour, and the death rate is in tumour associated death
Third position (Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer
statistics.CA Cancer J Clin,2011,61(2):69-90.).Factors are related to gastric cancer occurrence and development, packet
Include inherent cause, helicobacter pylori infections, unhealthy diet (such as high dose intake of salt and nitrate) and smoking, tobacco and wine
Deng.Due to lacking typical early symptom, the early diagnosis of gastric cancer is relatively difficult, has been in mostly when patients with gastric cancer is made a definite diagnosis
Advanced stage misses tumour best occasion for the treatment.Currently, operative treatment and chemicotherapy are the primary treatments (Macdonald of gastric cancer
JS,Smalley SR,et al.Chemoradiotherapy after surgery compared with surgery
alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J
Med, 2001,345 (10): 725-730.), but the biomarker due to lacking early diagnosis, prognostic indicator and effective
Therapy target, and frequent generation of recurrence of gastric cancer, DISTANT METASTASES IN and chemoresistance etc. factor makes gastric cancer totality poor prognosis, stomach
5 annual survival rate of cancer is about 40%.It is clinical improving gastric cancer although having the biological characteristics of many research and inquirement cancer
The effect that curative effect is played is very little.Research accordingly, with respect to the biological mechanism of gastric cancer occurrence and development has actively
Meaning.
In in the past few decades, the mutation that the research of gastric cancer is concentrated mainly on encoding key proteins gene participates in gastric cancer
(Nagarajan N, Bertrand D, Hillmer AM, et al.Whole-genome in terms of pathogenesis
reconstruction and mutational signatures in gastric cancer.Genome Biol,2012,
13(12):R115.).With the progress of sequencing technologies and genome analysis technology, it has been found that only Zhan is total for protein coding gene
The 2% of open gene, and most of gene is transcribed into nonprotein coding RNA (non-coding RNA, ncRNAs).Root
Two classes can be divided into according to the difference of its code length, one kind is small non-coding RNA, i.e., less than 200 nucleotide (nt) of length is short
Chain RNA, including microRNA (miRNAs), siRNA (siRNAs) RNA (piRNAs) related to Piwi；In addition a kind of non-coding
RNA, length are more than the long-chain non-coding RNA of 200 nucleotide, referred to as long-chain non-coding RNA (long non-coding
RNA, 1ncRNA), in recent years long-chain non-coding RNA attracted it is more and more researcher's note that more and more evidences
Show that lncRNAs can be by transcriptional level, the controlling gene of post-transcriptional level and epigenetics level locally or globally
Express (Mercer TR, Dinger ME, Mattick JS.Long non-coding RNAs:insights into
functions.Nat Rev Genet,2009,10(3):155-159.).It is played during gene expression in view of lncRNA
Important function, exception lncRNA expression has tissue specificity in gastric cancer, this makes lncRNA have diagnosing gastric cancer marker
Potentiality.
Summary of the invention
In order to make up for the deficiencies of the prior art, the purpose of the present invention is to provide a kind of biological markers relevant to gastric cancer
Object, the level by detecting biomarker may determine that the risk whether subject suffers from gastric cancer and get a cancer of the stomach；It is raw simultaneously
Object marker can be used as the therapeutic targets of gastric cancer, applied to the screening of therapeutic agent and the preparation of therapeutic agent.
To achieve the goals above, the present invention adopts the following technical scheme:
The present invention provides application of the reagent of molecular marker in detection sample in the product for preparing diagnosis of gastric cancer, institutes
State the one or two that molecular marker is selected from AC074117.10 or AC073283.7.
Further, the reagent is selected from:
The probe of specific recognition AC074117.10 or AC073283.7；Or
The primer of specific amplification AC074117.10 or AC073283.7.
Further, when timing in AC074117.10 or AC073283.7 expression, subject suffers from gastric cancer.
The present invention provides a kind of product of diagnosis of gastric cancer, the product include detect sample in AC074117.10 or
The reagent of AC073283.7.
Further, the product includes chip, kit.
Further, the reagent include reverse transcription PCR, real-time quantitative PCR, in situ hybridization, Northern blotting,
The reagent of chip or high-flux sequence detection of platform AC074117.10 or AC073283.7.
Further, it is included at least by the reagent that real-time quantitative PCR detects AC074117.10 or AC073283.7 a pair of special
The primer of specific amplification AC074117.10 or AC073283.7.
Further, the primer sequence of the specific amplification AC074117.10 is as shown in NO.1~2 SEQ ID, specificity
The primer of AC073283.7 is expanded as shown in NO.3~4 SEQ ID.
The present invention provides application of the AC074117.10 or AC073283.7 in the computation model of building prediction gastric cancer.
The present invention provides a kind of detection systems of gastric cancer, include:
1) for measuring the tool of molecular marker characteristic value in sample；
2) in comparative sample molecular marker characteristic value tool；
3) data storage medium.
The present invention provides application of the AC074117.10 or AC073283.7 in the drug of screening treatment gastric cancer.
The present invention provides application of the AC074117.10 or AC073283.7 in the drug of preparation treatment gastric cancer.
Detailed description of the invention
Fig. 1 is the expression figure using QPCR detection AC074117.10 or AC073283.7 gene in stomach organization,
Wherein figure A is AC074117.10, and figure B is AC073283.7.
Specific embodiment
The present invention is had found for the first time by the expression of detection stomach organization and the lncRNA in cancer beside organism
AC074117.10 and AC073283.7 expresses up-regulation in gastric cancer, by the expression for detecting AC074117.10 and AC073283.7
It is horizontal, it can be determined that the risk whether subject suffers from gastric cancer or get a cancer of the stomach provides new plan for the diagnosing and treating of gastric cancer
Slightly, while to disclose the pathogenesis of gastric cancer theoretical foundation is provided.
AC074117.10 gene is located on No. 2 chromosomes, including AC074117.10 gene and its homologue, mutation,
And isoform.The term covers overall length, unprocessed AC074117.10, and any type of from what is processed in cell
AC074117.10.The term covers the natural generation variant (such as splice variant or allelic variant) of AC074117.10.As
Non-limiting embodiment, AC074117.10 have such as ENST00000447070.1, ENST00000453289.1 or
Sequence shown in ENST00000412749.1.As a kind of representative embodiment, AC074117.10 has such as
Sequence shown in ENST00000447070.1.
AC073283.7 gene is located on No. 2 chromosomes, including AC073283.7 gene and its homologue, mutation, and
Isoform.The term covers overall length, unprocessed AC073283.7, and any type of from what is processed in cell
AC073283.7.The term covers the natural generation variant (such as splice variant or allelic variant) of AC073283.7.A kind of generation
The sequence of the AC073283.7 of table is as shown in ENST00000421759.1.
It will be appreciated by those skilled in the art that the means of measurement gene expression are not importances of the invention.It can be
The expression of biomarker is detected on transcriptional level.The present invention can use any method known in the art measurement base
Because of expression.
Terms used herein " differential expression " indicates to mark with one or more present invention biologies identical in second of sample
The expression of will object compares, after measured the amount or level of LncRNA, one or more biologies of the invention in a sample
The difference of one or more splice variant expressions of the RNA of the marker and/or biomarker lncRNA.Difference table
Up to can it is as described herein and those skilled in the art understand that method determine.Term " differential expression " or " change of expression
Change " indicate with biomarker given in second of sample measure expression compared with, the amount of RNA after measured, in sample
Given biomarker can measure increasing or decreasing for expression.Term " differential expression " or " variation of expression " may be used also
With indicate in second sample group biomarker measure expression compared with, in sample group give biomarker can
Measurement expression increases or decreases." differential expression " used herein can be opposite with the expression of given biomarker
The ratio that the Average expression level of biomarker is given in control is measured, and wherein ratio is not equal to 1.0.It can also use
P value measures differential expression.When using p value, when p value is less than 0.1, biomarker is accredited as in the first and second groups
Between differential expression.More preferable p value is less than 0.05.Even more preferably p value is less than 0.01.Even more preferably from p value less than 0.005.Most
It is preferred that p value is less than 0.001.When sketch-based user interface determines differential expression, if expression in the first and second of sample
Ratio is more than or less than 1.0, then RNA is differential expression.For example, the ratio greater than 1.2,1.5,1.7,2,3,4,10,20
Rate, or the ratio less than 1, such as 0.8,0.6,0.4,0.2,0.1,0.05.In another embodiment of the present invention, if
The ratio of the Average expression level of first group and the Average expression level of the second group is more than or less than 1.0, then transcribed nucleic acid
It originally is differential expression.For example, the ratio greater than 1.2,1.5,1.7,2,3,4,10,20, or the ratio less than 1, such as
0.8,0.6,0.4,0.2,0.1,0.05.In another embodiment of the present invention, if expression in first sample
Be more than or less than 1.0 with the ratio of Average expression level in second colony, be greater than 1.2 for example including ratio, 1.5,1.7,2,
3,4,10,20 or ratio less than 1, such as 0.8,0.6,0.4,0.2,0.1,0.05, then transcribed nucleic acid is originally differential expression.
" differential expression increase " or " up-regulation " indicates gene relative in contrast, and gene expression (with rna expression) is shown
Increase at least 10% or more, such as 20%, 30%, 40% or 50%, 60%, 70%, 80%, 90% or more or 1.1 times,
1.2 times, 1.4 times, 1.6 times, 1.8 times or more.
" differential expression reduction " or " downward " indicates gene relative in contrast, and gene expression (is measured) with rna expression
Display reduces at least 10% or more, such as 20%, 30%, 40% or 50%, 60%, 70%, 80%, 90% or less than 1.0
Again, 0.8 times, 0.6 times, 0.4 times, 0.2 times, 0.1 times or less gene.For example, up-regulation gene includes dividing with from normal individual
From the expression of RNA compare, the horizontal increased gene of rna expression from the sample of the individual separation characterized by with gastric cancer.
For example, down-regulated gene includes compared with the sample separated from normal individual, from the sample of the individual separation characterized by with gastric cancer
The gene that rna expression level reduces in this.
Normal individual in the present invention be for patients with gastric cancer or cancerous tissue, relative to patients with gastric cancer, non-cancer
Patient is normal individual；Relative to cancerous tissue, any normal tissue includes tissue (blood, gastric tissue from Healthy People
Deng) and cancer beside organism from patients with gastric cancer be normal individual.
LncRNA of the invention is detected using multiple nucleic acids technology known to persons of ordinary skill in the art, including but
It is not limited to reverse transcription PCR, real-time quantitative PCR, in situ hybridization, northern blotting, chip or high-flux sequence platform.
It is described to carry out detection including at least a pair of of specific amplified AC074117.10 or AC073283.7 base with reverse transcription PCR
The primer of cause；It is described to carry out detection including at least a pair of of specific amplified AC074117.10 or AC073283.7 with real-time quantitative PCR
The primer of gene；It is described to carry out the nucleic acid sequence detected include: with AC074117.10 or AC073283.7 gene in situ hybridization
The probe of hybridization；It is described with northern blot carry out detection include at least and AC074117.10 or AC073283.7 gene
The probe of nucleic acid array hybridizing；It is described to carry out the nucleic acid detected include: with AC074117.10 or AC073283.7 gene with chip
The probe of sequence hybridization.
In the present invention, term " primer " is meant, is capable of forming the base-pair (base complementary with template strand
Pair), and play the role of 7~50 nucleic acid sequences of the starting point for replicating template strand.Primer is usually synthesized into,
But the nucleic acid of nature generation also can be used.The sequence of primer is it is not absolutely required to identical with the sequence of template, as long as filling
Divide complementary and can hybridize with template.The addition feature for not changing the fundamental property of primer can be mixed into.As can mix
The example of the addition feature entered has methylation, replaces modification between nucleic acid by homologue with cap, more than one nucleic acid, but
It is without being limited thereto.
Term " probe ", which refers to, is as short as several nucleic acid fragment such as RNA or DNA to up to hundreds of bases, and the nucleic acid fragment can
To establish specific binding with mRNA and can determine the presence of specific mRNA because maintaining label (Labeling) effect.It visits
Needle can be by oligonucleotide probe, single stranded DNA (singlestrandedDNA) probe, double-stranded DNA
(doublestrandedDNA) prepared by the forms such as probe and rna probe.It in the present invention, can be by using mark of the invention
Remember that polynucleotides and complementary probe implement hybridization, by whether hybridizing and predict gastric cancer.It can be repaired based on content known in the art
Change the appropriate selection to probe and hybridization conditions.
The present invention provides application of the AC074117.10 or AC073283.7 in the computation model of preparation prediction gastric cancer.
It can be appreciated that, the measurement of two or more markers can be used to improve the diagnosis in investigation as those of skill in the art
Problem.Biochemical marker can measure individually, or in one embodiment of the invention, they can be measured simultaneously, example
Such as use chip or the array technique based on pearl.Then the independent concentration for interpreting biomarker, such as use every kind of marker
Individual retentions or they combine interpreted.
In the present invention, it can be implemented in various ways marker levels and certain possibility or risk association and realize
The step of getting up.Preferably, the mathematically measurement concentration of combination gene and one or more other markers, and by combined value
It associates with basic diagnosis problem.It can be by any suitable prior art mathematical method by the measurement group of marker levels
It closes.
Preferably, the mathematical algorithm applied in marker combination is a kind of logarithmic function.Preferably, using such mathematics
Algorithm or such logarithmic function the result is that single value.According to basic diagnosis problem, can easily by such value with it is for example a
Body associates about the risk of gastric cancer or with the other intentional diagnostic uses for helping to assess gastric cancer pine patient.With a kind of preferred
Mode, such logarithmic function obtains as follows: individual segregation a) is entered into group, such as normal person, have gastric cancer risk individual,
Patient etc. with gastric cancer, b) marker of the significant difference between these groups, c are identified by univariate analysis) logarithm
Regression analysis d) constructs logarithmic function to assess the independent difference value that can be used for assessing these difference groups of marker to combine
Independent difference value.In such analysis, marker is no longer independent, but represents a marker combination.
Logarithmic function for marker combination to be got up with disease association is preferably developed using by applied statistical method
With the algorithm of acquisition.For example, suitable statistical method is discriminant analysis (DA) (i.e. linear, secondary, regular DA), Kernel method
(i.e. SVM), nonparametric technique (i.e. k- nearest neighbor classifiers), PLS (partial least square), method (the i.e. logic based on tree
Recurrence, CART, random forest method, boosting/bagging method), generalized linear model (i.e. logarithm regression), the side based on principal component
Method (i.e. SIMCA), broad sense Additive Model, the method based on fuzzy logic, the method based on artificial neural network and genetic algorithms.Skillfully
Technical staff merges in the suitable statistical method of selection to assess marker group of the invention thus to obtain suitable mathematical algorithm
Aspect will not be problematic.In one embodiment, for obtaining the statistical method choosing of mathematical algorithm used in assessment gastric cancer
From DA (i.e. linear, secondary, rule based judgment analysis), Kernel method (i.e. SVM), (i.e. k- nearest-neighbors are classified for nonparametric technique
Device), PLS (partial least square), the method (i.e. logistic regression, CART, random forest method, propelled method) based on tree or
Generalized linear model (i.e. logarithm regression).
The present invention provides AC074117.10 or AC073283.7 to screen the application in the drug candidate for treating gastric cancer,
Include the following steps:
The system expressed or containing AC074117.10 or AC073283.7 gene is handled with substance to be screened；With
Detect the expression of AC074117.10 or AC073283.7 gene in the system；
Wherein, if the substance to be screened can inhibit the expression of AC074117.10 or AC073283.7 gene
It (preferably significantly reduces, such as low 20% or more, preferably low 50% or more；More preferably low 80% or more), then show the candidate
Matter is the drug candidate for treating gastric cancer.The system is selected from: cell system, subcellular system, solution system, organizational framework, device
Official's system or animal system.
The candidate substances include but is not limited to: for AC074117.10 or AC073283.7 gene or its upstream or
Disturbing molecule, nucleic acid inhibitor, the small molecule compound etc. of downstream gene design.
The present invention provides application of the AC074117.10 or AC073283.7 in the drug of preparation treatment gastric cancer.It is described
Drug includes the inhibitor and pharmaceutically acceptable carrier of AC074117.10 or AC073283.7.It is described pharmaceutically
The carrier of receiving includes but is not limited to diluent, adhesive, surfactant, Humectant, absorption carrier, lubricant, filling
Agent, disintegrating agent.
The present invention provides a kind of detection systems of gastric cancer, include:
1) for measuring the tool of molecular marker characteristic value in sample；
2) in comparative sample molecular marker characteristic value tool；
3) data storage medium.
Data storage medium storing data set in the present invention, term " data acquisition system " refer to physically and/or logic
The data acquisition system of upper set.Therefore, data acquisition system can implement to the physics in individual data storage medium or being linked to each other
In upper isolated data storage medium.Preferably, data acquisition system implements in database.Therefore, database as used herein
It include the data acquisition system on suitable storage medium.In addition, database preferably also includes data base management system.Data depositary management
Reason system is preferably based on the ranked data base management system of internet or in face of object database management system.In addition, data
Library can be federated database or integrated data base.It is highly preferred that database will be implemented as distributed (joint) system, such as
Client-Server-System.It is highly preferred that constructs database with allow searching algorithm come comparative test data group and comprising
The data group of data acquisition system.Especially, by using such algorithm, it may search for database (i.e. query search) and obtain instruction stomach
The similar or identical data group of cancer.Therefore, if identical or similar data group can be identified in data acquisition system, test
Data group will be related to gastric cancer.As a result, the information obtained from data acquisition system can be based on the test data obtained from subject
Group is used for diagnosis of gastric cancer.It is highly preferred that data acquisition system includes the characteristic value of any group of marker for including.
Term " data storage medium " includes being based on single physical entity such as CD, CD-ROM, hard disk, optical storage media or magnetic
The data storage medium or cloud disk of disk.In addition, the term further includes the data storage medium being made of physically separated entity,
The physically separated entity is preferably effectively connected with the suitable method of query search each other in a manner of providing above-mentioned data acquisition system
It connects.
" system " in the present invention is related to the different tools being linked to each other.The tool can implement in single device
Or it can be the physically separate device being linked to each other.Tool for comparing marker feature value, which is preferably based on, to be used for
The algorithm that compares and operated.Data storage medium preferably comprises above-mentioned data acquisition system or database, wherein storing data group
Each group of instruction break gastric cancer.Therefore, system of the invention allows to identify whether be stored in data storage medium data acquisition system
Include test data group.As a result, system of the invention can be used as the diagnostic tool of diagnosis of gastric cancer.
In the preferred embodiment of system, include the tool for measuring sample marker feature value.
Term " for measuring the tool of marker feature value " be preferably directed to for measure marker as nucleic acid amplification fill
It sets, nucleic acid hybridization equipment.
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, or according to the normal condition proposed by manufacturer.
Embodiment QPCR detects the expression of AC074117.10, AC073283.7 in gastric cancer
1, sample collection
Collect 35 patients with gastric adenocarcinoma cancerous tissue and corresponding cancer beside organism, all patients are preoperative not to carry out chemotherapy, puts
Treatment and endocrine therapy.
2, the preparation and quality analysis of RNA sample
Total tissue RNA is extracted using TRIZOL method
1) it is shredded with scissors tissue, 1ml Trizol is added, shakes 1min on oscillator；Room temperature 10min makes core egg
Lean type is decomposed completely.
2) 200 μ l chloroforms (chloroform) are added, cover tightly pipe lid, acutely shake 15s, room temperature stands 10min.
3) 4 DEG C, 11000rpm is centrifuged 15min.
4) water sample layer is transferred in a new centrifuge tube, 500 μ l isopropanols is added；After being mixed by inversion, room temperature is stood
10min。
5) 4 DEG C, 11000rpm is centrifuged 15min.
6) liquid is carefully siphoned away with rifle, stays and is deposited in tube bottom, the ethyl alcohol of 1ml 75% is added, shakes 5s on the oscillator,
Washing precipitating is primary.
7) 4 DEG C, 8000rpm is centrifuged 5min.
8) supernatant is carefully removed, drying precipitated 10min, suitable water dissolution precipitating 10min is added.
9) RNA concentration is detected, identifies the yield and purity of RNA.
3, reverse transcription:
It is operated using the reverse transcription reagent box (Takara code:DRR047A) of TAKARA company.
1) genomic DNA is removed
5 × gDNA Eraser B μ ffer, 2.0 μ l, gDNA Eraser, 1.0 μ l is added in test tube, 1 μ g of total serum IgE adds
Rnase Free ddH2O makes total volume to 10 μ l, 42 DEG C of heating 2min in water-bath.
2) reverse transcription reaction
By 5 ×2 4.0 μ l of Buffer,1.0 μ l of RT Enzyme Mix I,
1.0 μ l, RNase Free ddH of RTPrimer Mix24.0 μ l of O is added in above-mentioned test tube and is mixed together totally 20 μ l, water-bath
In 37 DEG C of 15min, 85 DEG C of 5s.
4, QPCR is expanded
1) design of primers
According to the gene order design primer of AC074117.10, AC073283.7 and GADPH, specific primer sequence is as follows:
AC074117.10 gene:
Forward primer is 5 '-CAGCCTCCTGAATAGTTG-3 ' (SEQ ID NO.1)；
Reverse primer is 5 '-GCAATATAGCAAGACCTCAT-3 ' (SEQ ID NO.2).
AC073283.7 gene:
Forward primer is 5 '-ACCTCTGATGAGATGATT-3 ' (SEQ ID NO.3)；
Reverse primer is 5 '-TTTCGTCTCCTCTACTTT-3 ' (SEQ ID NO.4).
GAPDH gene:
Forward primer is 5 '-AATCCCATCACCATCTTCCAG-3 ' (SEQ ID NO.5)；
Reverse primer is 5 '-GAGCCCCAGCCTTCTCCAT-3 ' (SEQ ID NO.6).
2) QPCR amplification is examined
WithPremix Ex TaqTMII (Takara Code:DRR081) kit configures PCR reaction system,
Thermal CyclerPCR amplification is carried out on Real Time System amplification instrument, confirms Real after reaction
The amplification curve and solubility curve of Time PCR, Δ Δ CT method carry out relative quantification.
Configure 25 μ l reaction systems:
Premix Ex TaqTM II (2 ×) 12.5 μ l, it is positive (anti-) to go out to each 1 μ l of primer, 2 μ l of DNA profiling
8.5 μ l of bacterium distilled water.
Reaction condition: 95 DEG C of 30s, (95 DEG C of 5s, 60 DEG C of 30s) × 40
5, using pROC R packet calculate AC074117.10 and AC073283.7 AUC value, judge AC074117.10 and
Diagnostic value of the AC073283.7 in gastric cancer.
6, result
QPCR result is as shown in Figure 1, compared with normal tissue, and AC074117.10 and AC073283.7 are in stomach organization
Expression up-regulation, difference have statistical significance (P < 0.05), wherein AC074117.10 raises about 1.91 times, on AC073283.7
Adjust about 4.52 times.
Bioinformatic analysis discovery, AC074117.10 and AC073283.7 diagnostic value with higher, wherein
The AUC value that the AUC value of AC074117.10 is 0.902, AC073283.7 is 0.888.
Simultaneously according to the correlation between AC074117.10 and AC073283.7 and gastric cancer generation, design is targeted
SiRNA, shRNA of AC074117.10 or AC073283.7 is applied to the treatment of gastric cancer and the preparation of pharmaceutical preparation.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Sequence table
<110>Surabaja county people's hospital
<120>application of the biomarker in gastric cancer detection, diagnosis
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
cagcctcctg aatagttg 18
<210> 2
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
gcaatatagc aagacctcat 20
<210> 3
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
acctctgatg agatgatt 18
<210> 4
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
tttcgtctcc tctacttt 18
<210> 5
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
aatcccatca ccatcttcca g 21
<210> 6
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
gagccccagc cttctccat 19
Claims (10)
1. detecting application of the reagent of molecular marker in sample in the product for preparing diagnosis of gastric cancer, which is characterized in that described
Molecular marker is selected from the one or two of AC074117.10 or AC073283.7.
2. application according to claim 1, which is characterized in that the reagent is selected from:
The probe of specific recognition AC074117.10 or AC073283.7；Or
The primer of specific amplification AC074117.10 or AC073283.7.
3. application according to claim 1 or 2, which is characterized in that when AC074117.10 or AC073283.7 expression up-regulation
When, subject suffers from gastric cancer.
4. a kind of product of diagnosis of gastric cancer, which is characterized in that the product include detect sample in AC074117.10 or
The reagent of AC073283.7.
5. product according to claim 4, which is characterized in that the product includes chip, kit.
6. product according to claim 4, which is characterized in that the reagent includes passing through reverse transcription PCR, real-time quantitative
PCR, in situ hybridization, northern blotting, chip or high-flux sequence detection of platform AC074117.10 or
The reagent of AC073283.7.
7. product according to claim 6, which is characterized in that by real-time quantitative PCR detect AC074117.10 or
The reagent of AC073283.7 includes at least the primer of a pair of of specific amplification AC074117.10 or AC073283.7.
8. product according to claim 7, which is characterized in that the primer sequence of the specific amplification AC074117.10
As shown in NO.1~2 SEQ ID, the primer of specific amplification AC073283.7 is as shown in NO.3~4 SEQ ID.
9.AC074117.10 or application of the AC073283.7 in the computation model of building prediction gastric cancer.
10. a kind of detection system of gastric cancer, characterized by comprising:
1) for measuring the tool of molecular marker characteristic value in sample；
2) in comparative sample molecular marker characteristic value tool；
3) data storage medium.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910684287.7A CN110358835A (en) | 2019-07-26 | 2019-07-26 | Application of the biomarker in gastric cancer is detected, diagnosed |
| CN201910914547.5A CN110452989B (en) | 2019-07-26 | 2019-09-26 | Application of biomarker in detection and diagnosis of gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910684287.7A CN110358835A (en) | 2019-07-26 | 2019-07-26 | Application of the biomarker in gastric cancer is detected, diagnosed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110358835A true CN110358835A (en) | 2019-10-22 |
Family
ID=68222031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910684287.7A Pending CN110358835A (en) | 2019-07-26 | 2019-07-26 | Application of the biomarker in gastric cancer is detected, diagnosed |
| CN201910914547.5A Active CN110452989B (en) | 2019-07-26 | 2019-09-26 | Application of biomarker in detection and diagnosis of gastric cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910914547.5A Active CN110452989B (en) | 2019-07-26 | 2019-09-26 | Application of biomarker in detection and diagnosis of gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110358835A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112501259A (en) * | 2020-11-30 | 2021-03-16 | 广东医科大学 | Long-chain non-coding RNA chromogenic in situ hybridization kit and detection method |
| CN113388682A (en) * | 2021-06-18 | 2021-09-14 | 福建医科大学附属第一医院 | Gene-based product for diagnosing gastric cancer and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014239309B2 (en) * | 2013-03-15 | 2020-03-05 | Beth Israel Deaconess Medical Center, Inc. | miRNA biogenesis in exosomes for diagnosis and therapy |
| CN106755513B (en) * | 2017-02-08 | 2018-10-19 | 泰山医学院 | A kind of lncRNA markers of gastric cancer |
| WO2019079647A2 (en) * | 2017-10-18 | 2019-04-25 | Wuxi Nextcode Genomics Usa, Inc. | Statistical ai for advanced deep learning and probabilistic programing in the biosciences |
| CN108531596B (en) * | 2018-04-25 | 2022-03-25 | 成都望路医药技术有限公司 | Application of lncRNA as biomarker in diagnosis and treatment of gastric cancer |
-
2019
- 2019-07-26 CN CN201910684287.7A patent/CN110358835A/en active Pending
- 2019-09-26 CN CN201910914547.5A patent/CN110452989B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112501259A (en) * | 2020-11-30 | 2021-03-16 | 广东医科大学 | Long-chain non-coding RNA chromogenic in situ hybridization kit and detection method |
| CN113388682A (en) * | 2021-06-18 | 2021-09-14 | 福建医科大学附属第一医院 | Gene-based product for diagnosing gastric cancer and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110452989A (en) | 2019-11-15 |
| CN110452989B (en) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yao et al. | The long noncoding RNA TTTY15, which is located on the Y chromosome, promotes prostate cancer progression by sponging let-7 | |
| Huang et al. | Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer | |
| Bloomston et al. | MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis | |
| JP7186700B2 (en) | Methods to Distinguish Tumor Suppressor FOXO Activity from Oxidative Stress | |
| CN102719525B (en) | Primer, probe and detection kit for detection of EML4-ALK fusion gene mutation | |
| JP6280206B2 (en) | Prognosis prediction system for locally advanced gastric cancer | |
| AU2017261442B2 (en) | Detection of chromosome interaction relevant to breast cancer | |
| JP2010535473A5 (en) | ||
| US20220177976A1 (en) | Colorectal cancer screening method and device | |
| US20230227914A1 (en) | Biomarkers of oral, pharyngeal and laryngeal cancers | |
| CN109563544A (en) | The diagnostic assay of urine monitoring for bladder cancer | |
| Langevin et al. | Novel DNA methylation targets in oral rinse samples predict survival of patients with oral squamous cell carcinoma | |
| CN109735624A (en) | Application of gene markers in the diagnosis of thyroid cancer | |
| JP6611411B2 (en) | Pancreatic cancer detection kit and detection method | |
| CN110358835A (en) | Application of the biomarker in gastric cancer is detected, diagnosed | |
| CN111187840A (en) | Biomarker for early breast cancer diagnosis | |
| CN110055332A (en) | Marker relevant to thyroid cancer and its application | |
| US20130084241A1 (en) | DEVELOPMENT OF miRNA DIAGNOSTICS TOOLS IN BLADDER CANCER | |
| CN109913554A (en) | A kind of lncRNA marker relevant to breast cancer | |
| CN110093422A (en) | Application of the LINC02159 in adenocarcinoma of lung diagnosis and treatment | |
| CN109825595A (en) | LncRNA marker relevant to breast cancer and its detection primer and application | |
| CN116287180A (en) | Application of reagent for detecting marker in preparation of kit for diagnosing asthma | |
| EP2906713A1 (en) | Micro-rna biomarkers for prostate cancer | |
| CN110042164B (en) | Lung cancer diagnosis and treatment lncRNA marker | |
| CN110055333A (en) | Application of the RP11-116O18.1 as molecular marker in lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |